Developing Next-Generation Immunotherapies
Kleo is based in New Haven, CT and was founded in 2016 by Dr. David Spiegel and Roy Prieb to translate Dr. Spiegel's research in small molecule immunotherapies at Yale University into clinical treatments. Kleo’s mission is to create fully synthetic compounds that recruit the immune system to destroy cancer cells, but with significant advantages compared to biologics.
Kleo’s unique technologies are scientifically validated and proprietary. Proof of concept has been established in multiple in vitro and in vivo models, and the company’s technology and approach have been vetted by strategic investors Biohaven Pharmaceuticals and PeptiDream. The company is well-funded to achieve multiple preclinical and early clinical milestones, with its lead compound expected to commence human studies in 2020.